← All trials
NCT07193459
Phase 3Interventional
Includes trials conducted after preliminary evidence suggesting effectiveness of the drug has been obtained, and are intended to gather additional information to evaluate the overall benefit-risk relationship of the drug.
View on ClinicalTrials.gov ↗Timeline
- Start date
- Aug 12, 2025
- Primary completion
- Oct 10, 2026
- Completion date
- Feb 1, 2027
- First posted
- Sep 25, 2025
- Last posted
- Sep 25, 2025
- Enrollment
- 360
- Arms / groups
- 3 / —
- Source
- AACT · ctgov ingestion
Sponsors
- Hangzhou ZhongmeiLead sponsor
Drugs studied
Indications studied
CDEK-curated fields only — the ClinicalTrials.gov results mirror (baseline measures, adverse events, participant flow) is a separate, currently-dormant pipeline; see MIGRATION_PLAN.md.